Who are norepinephrine+vasopressin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Norepinephrine and Vasopressin for Rescue.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/norepinephrine-vasopressin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

norepinephrine+vasopressin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

norepinephrine+vasopressin (norepinephrine+vasopressin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressor combination. Area: Critical Care / Cardiovascular.

marketed Vasopressor combination Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, vasopressin V1 receptor Critical Care / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

norepinephrine+vasopressin (norepinephrine+vasopressin) — Peking Union Medical College Hospital. This combination of norepinephrine and vasopressin acts as a dual vasopressor agent that increases blood pressure and tissue perfusion through alpha-adrenergic stimulation and vasopressin V1 receptor activation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
norepinephrine+vasopressin TARGET	norepinephrine+vasopressin	Peking Union Medical College Hospital	marketed	Vasopressor combination	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, vasopressin V1 receptor
Norepinephrine and Vasopressin for Rescue	Norepinephrine and Vasopressin for Rescue	Hospital do Coracao	phase 3	Vasopressor combination	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, V1 vasopressin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressor combination class)

Hospital do Coracao · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). norepinephrine+vasopressin — Competitive Intelligence Brief. https://druglandscape.com/ci/norepinephrine-vasopressin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing